Employment-Based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2008 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Johns Hopkins University
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00249496
First received: November 3, 2005
Last updated: May 28, 2008
Last verified: May 2008

November 3, 2005
May 28, 2008
October 2003
Not Provided
  • Percentage of urine samples at the 30-day assessments that are negative for cocaine
  • Percentage of Monday, Wednesday and Friday urine samples that are negative for cocaine
Same as current
Complete list of historical versions of study NCT00249496 on ClinicalTrials.gov Archive Site
  • HIV risk behaviors
  • Percentage of 30-day assessment urine samples negative for opiates
  • Percentage of 30-day assessments that subjects report complete opiate abstinence
  • Percentage of Monday, Wednesday and Friday urine samples that are negative for opiates
  • HIV risk behaviors
  • Percentage of 30-day assessment urine samples negative for opiates
  • Percentage of 30-day assessments that subjects report complete opiate abstinence
Not Provided
Not Provided
 
Employment-Based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1
Therapeutic Workplace Maintenance Study

This application is a competing continuation of a grant in which we developed and pilot tested a computerized Therapeutic Workplace designed to train and employ adults as data entry operators. A randomized trial is planned over 5 years to investigate the Therapeutic Workplace business as a maintenance intervention to sustain long-term abstinence and employment. Welfare recipients in methadone treatment, actively using cocaine, and at risk for contracting or spreading HIV infection will participate in an initial Therapeutic Workplace training phase. Participants (N=104) who become abstinent and skilled will be randomly assigned to an Abstinence & Employment, or an Employment Only group. Participants in the Abstinence & Employment group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary. Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work. This study will provide a rigorous evaluation of the efficacy of the Therapeutic Workplace business as a long-term treatment of cocaine addiction and unemployment; determine the benefits of requiring daily evidence of abstinence to work; and provide information on the extent to which a Therapeutic Workplace business can become self-sustaining. This research could provide firm scientific foundation for the dissemination of Therapeutic Workplace businesses in the long-term treatment of cocaine addiction and unemployment. The main hypothesis being tested is that cocaine abstinence will be reliably maintained during the yearlong intervention evaluation period only in the group exposed to the explicit abstinence maintenance intervention. We expect that cocaine abstinence in the Abstinence and Employment group will be significantly greater than cocaine abstinence in the Employment Only group.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Alcohol Use
  • Drug Use
  • Sexual Risk Behaviors
Behavioral: Contingency management
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
390
Not Provided
Not Provided

Inclusion Criteria:

  • Applicants in methadone treatment may be eligible to participate in Phase 1 of the study.
  • Applicants will be blind to the full details of the eligibility criteria.
Both
18 Years and older
No
Contact: Karly N Diemer, M.A., B.S. (410)550-6723 kdiemer@jhmi.edu
United States
 
NCT00249496
NIDA-13107-1, R01-13107-1
No
Not Provided
National Institute on Drug Abuse (NIDA)
Johns Hopkins University
Principal Investigator: Kenneth Silverman, Ph.D. Johns Hopkins University
National Institute on Drug Abuse (NIDA)
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP